The Financial Times notes that Merck's Januvia could be approved by the FDA as early as today. Januvia is a new type of diabetes drug that regulates sugar and insulin production. Analysts expect Januvia to be a blockbuster, which would be a welcome relief to the embattled Merck. But Merck won't own the DPP-IV inhibitor market for long. Novartis' Galvus is expected to get an approval next month.
- here's the report from MarketWatch on Januvia
PLUS: An approval will trigger widespread use. Report
ALSO: Pfizer and Eisai won U.S. regulatory approval to expand the use of Aricept to more serious cases of Alzheimer's. Report